Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

Overview

Journal Arthritis Care Res (Hoboken)

Specialty Rheumatology

Date 2016 Jan 28

PMID 26815944

Citations 30

Authors

M Rudwaleit

J T Rosenbaum

R Landewe

H Marzo-Ortega

J Sieper

D van der Heijde

O Davies

H Bartz

B Hoepken

T Nurminen

A Deodhar

Affiliations

Soon will be listed here.

Abstract

Objective: Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine and sacroiliac joints and can also affect extraarticular sites, with the most common manifestation being uveitis. Here we report the incidence of uveitis flares in axial SpA patients from the RAPID-axSpA trial, including ankylosing spondylitis (AS) and nonradiographic (nr) axial SpA.

Methods: The RAPID-axSpA (NCT01087762) trial is double-blind and placebo-controlled to week 24, dose-blind to week 48, and open-label to week 204. Patients were randomized to certolizumab pegol (CZP) or placebo. Placebo patients entering the dose-blind phase were re-randomized to CZP. Uveitis events were recorded on extraarticular manifestation or adverse event forms. Events were analyzed in patients with/without history of uveitis, and rates reported per 100 patient-years.

Results: At baseline, 38 of 218 CZP-randomized patients (17.4%) and 31 of 107 placebo-randomized patients (29.0%) had past uveitis history. During the 24-week double-blind phase, the rate of uveitis flares was lower in CZP (3.0 [95% confidence interval (95% CI) 0.6-8.8] per 100 patient-years) than in placebo (10.3 [95% CI 2.8-26.3] per 100 patient-years). All cases observed during the 24-week double-blind phase were in patients with a history of uveitis; in these patients, rates were similarly lower for CZP (17.1 [95% CI 3.5-50.1] per 100 patient-years) than placebo (38.5 [95% CI 10.5-98.5] per 100 patient-years). Rates of uveitis flares remained low up to week 96 (4.9 [95% CI 3.2-7.4] per 100 patient-years) and were similar between AS (4.4 [95% CI 2.3-7.7] per 100 patient-years) and nr-axial SpA (5.6 [95% CI 2.9-9.8] per 100 patient-years).

Conclusion: The rate of uveitis flares was lower for axial SpA patients treated with CZP than placebo during the randomized controlled phase. Incidence of uveitis flares remained low to week 96 and was comparable to rates reported for AS patients receiving other anti-tumor necrosis factor antibodies.

Citing Articles

Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment.

Faggiani I, Fanizza J, DAmico F, Allocca M, Zilli A, Parigi T Biomedicines. 2024; 12(8).

PMID: 39200303 PMC: 11351332. DOI: 10.3390/biomedicines12081839.

Use of immunomodulators in non-infectious uveitis: lights and shadows.

Bernal-Morales C, Ramanan A, Pavesio C Eye (Lond). 2024; 38(17):3231-3242.

PMID: 39160332 PMC: 11584895. DOI: 10.1038/s41433-024-03294-9.

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.

Rudwaleit M, Deodhar A, Bauer L, Gensler L, Hoepken B, Kumke T RMD Open. 2024; 10(2).

PMID: 38724259 PMC: 11086426. DOI: 10.1136/rmdopen-2023-003884.

Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors.

Kwon H, Kim Y, Kim T, Ahn S J Clin Med. 2024; 13(3).

PMID: 38337605 PMC: 10856241. DOI: 10.3390/jcm13030912.

Ocular Manifestations of Spondyloarthritis.

Pandey A, Ravindran V Mediterr J Rheumatol. 2023; 34(1):24-29.

PMID: 37223599 PMC: 10201097. DOI: 10.31138/mjr.34.1.24.

References

Wallis D, Haroon N, Ayearst R, Carty A, Inman R . Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases?. J Rheumatol. 2013; 40(12):2038-41. DOI: 10.3899/jrheum.130588. View

Levy-Clarke G, Jabs D, Read R, Rosenbaum J, Vitale A, Van Gelder R . Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2013; 121(3):785-96.e3. DOI: 10.1016/j.ophtha.2013.09.048. View

Dougados M, DAgostino M, Benessiano J, Berenbaum F, Breban M, Claudepierre P . The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine. 2011; 78(6):598-603. DOI: 10.1016/j.jbspin.2011.01.013. View

Benitez-Del-Castillo J, Garcia-Sanchez J, Iradier T, Banares A . Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000; 14 ( Pt 3A):340-3. DOI: 10.1038/eye.2000.84. View

Boonen A, van der Linden S . The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006; 78:4-11. View

Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D . Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. 2002; 28(12):2667-73. View

Braun J, Baraliakos X, Listing J, Sieper J . Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005; 52(8):2447-51. DOI: 10.1002/art.21197. View

van der Horst-Bruinsma I, Nurmohamed M . Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012; 4(6):413-22. PMC: 3512172. DOI: 10.1177/1759720X12458372. View

Rosenbaum J, Rosenzweig H . Spondyloarthritis: the eyes have it: uveitis in patients with spondyloarthritis. Nat Rev Rheumatol. 2012; 8(5):249-50. PMC: 3343203. DOI: 10.1038/nrrheum.2012.43. View

10.

Lim L, Fraunfelder F, Rosenbaum J . Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007; 56(10):3248-52. DOI: 10.1002/art.22918. View

11.

Sanchez-Cano D, Callejas-Rubio J, Ruiz-Villaverde R, Rios-Fernandez R, Ortego-Centeno N . Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm. 2013; 2013:286857. PMC: 3747407. DOI: 10.1155/2013/286857. View

12.

Rosenbaum J, Smith J . Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol. 2002; 20(6 Suppl 28):S143-5. View

13.

Wendling D, Paccou J, Berthelot J, Flipo R, Guillaume-Czitrom S, Prati C . New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011; 41(3):503-10. DOI: 10.1016/j.semarthrit.2011.05.005. View

14.

Munoz-Fernandez S, Garcia-Aparicio A, Hidalgo M, Platero M, Schlincker A, Bascones M . Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye (Lond). 2008; 23(5):1130-3. DOI: 10.1038/eye.2008.198. View

15.

Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C . Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?. Arthritis Care Res (Hoboken). 2012; 64(9):1415-22. DOI: 10.1002/acr.21688. View

16.

Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych W, Mease P . Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2013; 73(1):39-47. PMC: 3888598. DOI: 10.1136/annrheumdis-2013-204231. View

17.

van der Horst-Bruinsma I, Nurmohamed M, Landewe R . Comorbidities in patients with spondyloarthritis. Rheum Dis Clin North Am. 2012; 38(3):523-38. DOI: 10.1016/j.rdc.2012.08.010. View

18.

Llorenc V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maiz O . Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm. 2014; 24(2):167-72. DOI: 10.3109/09273948.2014.967779. View

19.

Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Bonilla G, Ruiz-Sancho D . Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003; 30(6):1277-9. View

20.

Smolen J, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P . Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2013; 73(1):6-16. PMC: 3888616. DOI: 10.1136/annrheumdis-2013-203419. View